The Uromigos
By The Uromigos
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by The Uromigos
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 3
Reviews: 0
Episodes: 314
Description
Broadcasting the latest developments in GU cancer
Hosted by Brian Rini and Tom Powles
Brian Rini MD is Chief of Clinical Trials, Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Centre
Tom Powles is Director of Barts Cancer Centre, St Bartholomews Hospital and Professor or Genitourinary oncology, Queen Mary University of London
| Episode | Date |
|---|---|
|
Episode 316: APCCC 2024 Summary with Silke Gillessen
|
Apr 28, 2024 |
|
Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer
|
Apr 27, 2024 |
|
Episode 314: APCCC 2024 Cardiovascular risks with hormone therapy in prostate cancer
|
Apr 27, 2024 |
|
Episode 313: APCCC 2024 Debate - Radiation therapy in advanced disease
|
Apr 26, 2024 |
|
Episode 312: APCCC 2024 Radiation therapy after surgery for prostate cancer
|
Apr 26, 2024 |
|
Episode 311: The Uromigos Paper of the Month - The POUT Trial
|
Apr 23, 2024 |
|
Episode 310: Dosing and duration of drugs from a cost perspective
|
Apr 17, 2024 |
|
Episode 309: EAU24 Checkmate 274 - OS for adjuvant nivolumab in bladder cancer
|
Apr 07, 2024 |
|
Episode 308: EAU24 IMVIGOR 011 - Outcome of ctDNA negative patients post-cystectomy
|
Apr 07, 2024 |
|
Episode 307: Bladder-Sparing Approaches Part 2
|
Apr 02, 2024 |
|
Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC
|
Mar 28, 2024 |
|
Episode 305: FDA and Oncology Clinical Trials
|
Mar 19, 2024 |
|
Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC
|
Mar 11, 2024 |
|
Episode 303: Community GU Oncology
|
Mar 05, 2024 |
|
Episode 302: Part 2- Adjuvant Therapy in solid tumors
|
Feb 25, 2024 |
|
Episode 301: Cancer research from a global perspective.
|
Feb 20, 2024 |
|
Episode 300: Adjuvant PD1 Therapy in Solid Tumours
|
Feb 11, 2024 |
|
Episode 299: Androgen receptor ligand-directed degrader BMS-986365
|
Feb 07, 2024 |
|
Episode 298: ASCO GU 2024 Highlights
|
Jan 31, 2024 |
|
Episode 297: ASCO GU 2024: CONTACT2 Part 2 - The Aftermath
|
Jan 30, 2024 |
|
Episode 296: ASCO GU 2024: Novel approaches to QOL and belzutifan
|
Jan 27, 2024 |
|
Episode 295: ASCO GU 2024: Adjuvant Therapy in Renal Cancer
|
Jan 27, 2024 |
|
Episode 294: ASCO GU 2024: Adjuvant Pembrolizumab in Bladder Cancer
|
Jan 27, 2024 |
|
Episode 293: ASCO GU 2024: BRCAaway and CONTACT2
|
Jan 26, 2024 |
|
Episode 292: ASCO GU 2024: HPN328 - A Tri-Specific T Cell Engager in Prostate Cancer
|
Jan 26, 2024 |
|
Episode 291: ASCO GU 2024: CONTACT2 - Cabozantinib and Atezolizumab in Prostate Cancer
|
Jan 25, 2024 |
|
Episode 290: ASCO GU 2024 Preview
|
Jan 17, 2024 |
|
Episode 289: The Uromigos Paper of the Month - TALAPRO2 in Nature Medicine
|
Jan 15, 2024 |
|
Episode 288: APCCC #3: Controversies around Radiotherapy
|
Jan 10, 2024 |
|
Episode 287 APCCC: Early Discontinuation of Therapy in HSPC
|
Jan 04, 2024 |
|
Episode 286: APCCC Prostate Cancer Meeting Overview
|
Jan 03, 2024 |
|
Episode 285: Holiday Special: Renal Cancer in 2023
|
Dec 22, 2023 |
|
Episode 284: Tres amigas: Lo más destacado del cáncer en urología en 2023
|
Dec 21, 2023 |
|
Episode 283: Holiday Special: Prostate Cancer in 2023
|
Dec 20, 2023 |
|
Episode 282: Holiday Special: Bladder Cancer in 2023
|
Dec 13, 2023 |
|
Episode 281: The Uromigos Paper of the Month - Lu-177 with Pembrolizumab in Prostate Cancer
|
Dec 08, 2023 |
|
Episode 280: IKCS 2023 Overview
|
Nov 16, 2023 |
|
An apology
|
Nov 13, 2023 |
|
Episode 279: Management of IO-resistant RCC at #UromigosLive 2023
|
Nov 06, 2023 |
|
Episode 278: Current and Future Status of Radioligand Therapy at #UromigosLive 2023
|
Nov 04, 2023 |
|
Episode 277: NMIBC Discussion at #UromigosLive 2023
|
Nov 04, 2023 |
|
Episode 276: ESMO 2023 Highlights
|
Oct 28, 2023 |
|
Episode 275: Live meeting preview for #UromigosLive 2023 in Nashville
|
Oct 27, 2023 |
|
Episode 274: ESMO 2023 STEAP1/BiTE in CRPC shows promise
|
Oct 27, 2023 |
|
Episode 273: ESMO 2023 - Toripalimab and axitinib in clear cell RCC
|
Oct 26, 2023 |
|
Episode 272: ESMO 2023 - EV302 and CM901 in 1st line bladder cancer
|
Oct 22, 2023 |
|
Episode 271: ESMO 2023 - THOR: Erdafitinib in bladder cancer
|
Oct 22, 2023 |
|
Episode 270: ESMO 2023 - Belzutifan in renal cancer
|
Oct 21, 2023 |
|
Episode 269: ESMO 2023 - antibody drug conjugate doublets in UC
|
Oct 21, 2023 |
|
Episode 268: ESMO 2023 - Enzalutamide and 177Lu-PSMA-617 in CRPC with Louise Emmett
|
Oct 20, 2023 |
|
Episode 267: ESMO preview - things to look out for at the meeting
|
Oct 11, 2023 |
|
Episode 266: Radiotherapy for prostate cancer
|
Oct 10, 2023 |
|
Episode 265: Brachytherapy with Jeff Michalski
|
Oct 03, 2023 |
|
Episode 264: Prostatectomy vs RT vs surveillance- the PROTECT trial
|
Sep 27, 2023 |
|
Episode 263: Toni Choueiri and papillary renal cancer
|
Sep 20, 2023 |
|
Episode 262: Paper of the month abiraterone +/- cabazitaxel in CRPC.
|
Sep 12, 2023 |
|
Episode 261: part 2 ctDNA in bladder cancer
|
Sep 04, 2023 |
|
Episode 260: Celeste Simon: how to make a career in translation science work.
|
Aug 30, 2023 |
|
Episode 259: Cystectomy for bladder cancer
|
Aug 24, 2023 |
|
Episode 258: Curative radiotherapy for bladder cancer: Golden Ticket Winner #1
|
Aug 15, 2023 |
|
Episode 257: Chana Weinstock from the FDA
|
Aug 07, 2023 |
|
Episode 256: ctDNA in urothelial studies.
|
Jul 27, 2023 |
|
Episode 255: How to get an academic paper accepted
|
Jul 26, 2023 |
|
Episode 254: New RCC studies at KCRS 2023 with Laurence Albiges
|
Jul 17, 2023 |
|
Episode 253: Patients' perspectives on adjuvant and 1st line RCC
|
Jul 13, 2023 |
|
Episode 252: Talazoparib and its FDA approval in CRPC
|
Jul 04, 2023 |
|
Episode 251: Final part of VEGF/TKI vs IPI/NIVO discussion
|
Jun 26, 2023 |
|
Episode 250: Bob Motzer discusses IPI/Nivo vs VEGF/PD1
|
Jun 18, 2023 |
|
Episode 249: ASCO 2023 emergency podcast IPI/NIVO vs VEGF/PD1 in kidney cancer
|
Jun 18, 2023 |
|
Episode 248: ASCO23 GU highlights
|
Jun 14, 2023 |
|
Episode 246: ASCO 2023: EV pembro and erdafitinib +/- cetrelimab in 1st line UC
|
Jun 05, 2023 |
|
Episode 245: ASCO 2023 - CONTACT-03 cabozantinib +/- atezolizumab in renal cancer
|
Jun 05, 2023 |
|
Episode 244: ASCO 2023 PEACE-1 in CRPC
|
Jun 05, 2023 |
|
Episode 243: ASCO 2023 TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide
|
Jun 05, 2023 |
|
Episode 242: ASCO 2023 THOR study - erdafitinib vs chemo in bladder cancer
|
Jun 05, 2023 |
|
Episode 241: Statistics for clinical trials
|
Jun 01, 2023 |
|
Episode 240: Preview of GU Cancer at ASCO 2023
|
May 30, 2023 |
|
Episode 239: The STAMPEDE trial
|
May 22, 2023 |
|
Episode 238: Paper of the month: Biomarkers for neoadjuvant PD(L)1 therapy
|
May 14, 2023 |
|
Episode 237: 2023 AUA Highlights
|
May 09, 2023 |
|
Episode 236: ODAC for olaparib
|
May 02, 2023 |
|
Episode 235: Danny Heng and the IMDC classification in renal cancer
|
Apr 24, 2023 |
|
Episode 234: Amar Kishan, MD, on Neoadjuvant or Adjuvant Radiotherapy for Prostate Cancer
|
Apr 19, 2023 |
|
Episode 233: Destaques da 14ª reunião internacional brasileira de câncer urológico
|
Apr 15, 2023 |
|
Episode 232: Belzutifan in early and late renal cancer
|
Apr 14, 2023 |
|
Episode 231: Ursula Vogl, MD in the Rising Star Series
|
Apr 05, 2023 |
|
Episode 230: FGFR Inhibition in NMIBC With Sia Daneshmand
|
Mar 28, 2023 |
|
Episode 229: Kala Sridhar, MD on PET in Early Bladder Cancer
|
Mar 20, 2023 |
|
Episode 228: Karine Tawagi, MD in the Rising Star Series
|
Mar 15, 2023 |
|
Episode 227: 2023 ASCO GU Bladder Highlights and Paper of the Month with Michiel Van der Heijden
|
Mar 06, 2023 |
|
Episode 226: 2023 ASCO GU Prostate and RCC Highlights With Dan George
|
Feb 27, 2023 |
|
Episode 225: ASCO GU 2023: Brian Shuch, MD discusses the ZIRCON Phase III Study of girentuximab PET/CT imaging in RCC
|
Feb 20, 2023 |
|
Episode 224: ASCO GU 2023: discussing miR371 for Germ Cell Tumors with Christian Kollmannsberger
|
Feb 20, 2023 |
|
Episode 223: ASCO GU 2023: Discussing KEYNOTE-057 with Andrea Necchi, MD
|
Feb 17, 2023 |
|
Episode 222: ASCO GU 2023: New Data From IMvigor130 with Enrique Grande, MD
|
Feb 17, 2023 |
|
Episode 221: ASCO GU 2023: Matt Galsky, MD Gives an Update on the CheckMate 274 Trial
|
Feb 17, 2023 |
|
Episode 220: ASCO GU 2023: Discussing PARPi for CRPC with Michael Morris, MD
|
Feb 17, 2023 |
|
Episode 219: ASCO GU 2023: Neeraj Agarwal, MD, FASCO Discusses the TALAPRO-2 study
|
Feb 17, 2023 |
|
Episode 218: Discussing The Cost of Cancer Drugs With Daniel Goldstein, MD
|
Feb 07, 2023 |
|
Episode 217: Rising Star: Vadim Koshkin and ADCs
|
Feb 03, 2023 |
|
Episode 216: ADCs in Bladder Cancer With Petros Grivas, MD, PhD
|
Jan 30, 2023 |
|
Episode 215: Resumen cáncer de próstata y vejiga reunión Canarias
|
Jan 21, 2023 |
|
Episode 214: Resumen de la reunión en las Islas Canarias sobre cáncer renal
|
Jan 21, 2023 |
|
Episode 213: IL-15RaFc superagonist in NMIBC
|
Jan 09, 2023 |
|
Episode 212: What's coming in GU Cancers in 2023
|
Jan 02, 2023 |
|
Episode 211: CAR-T cell therapy in RCC
|
Dec 29, 2022 |
|
Episode 210: Christmas Prostate Cancer Debate - olaparib and abiraterone in selected or unselected patients
|
Dec 22, 2022 |
|
Episode 209: Christmas Bladder Cancer Debate - Cisplatin vs carboplatin in bladder cancer
|
Dec 17, 2022 |
|
Episode 208: Christmas Kidney Cancer Debate - Ipilimumab in renal cancer
|
Dec 12, 2022 |
|
Episode 207: Editorial on COSMIC-313
|
Dec 05, 2022 |
|
Episode 206: Dan Shapiro in the Rising Star series
|
Nov 28, 2022 |
|
Episode 205: Paper of the Month - Nab-paclitaxel and pembrolizumab in bladder cancer
|
Nov 21, 2022 |
|
Episode 204: Scott Haake in the Rising Star series
|
Nov 14, 2022 |
|
Episode 203: Renee Saliby in the Rising Star series
|
Nov 14, 2022 |
|
Episode 202: The Uromigos Paper of the Month - Docetaxel with or without continuous enza in CRPC
|
Nov 07, 2022 |
|
Episode 201: PARPi in CRPC
|
Nov 01, 2022 |
|
Episode 200: Chromophobe renal cancer
|
Oct 25, 2022 |
|
Episode 199: The Uromigos Paper of the Month - FGFR inhibition in bladder cancer
|
Oct 17, 2022 |
|
Episode 198: The RADICALS trial in prostate cancer
|
Oct 07, 2022 |
|
Episode 197: The Uromigos Nashville 2022
|
Sep 29, 2022 |
|
Episode 196: The COSMIC-313 Trial cabo/ipi/nivo in 1st line renal cancer
|
Sep 14, 2022 |
|
Episode 195 ESMO 2022: EV Pembrolizumab in 1st line bladder cancer
|
Sep 13, 2022 |
|
Episode 194 ESMO 2022: Pegylated il-2 + nivolumab in renal cancer
|
Sep 12, 2022 |
|
Episode 193 ESMO 2022: PRESTO - a phase III trial of androgen annihilation in biochemically relapsed prostate cancer
|
Sep 11, 2022 |
|
Episode 192 ESMO 2022: Summary of ESMO Adjuvant RCC Trials
|
Sep 11, 2022 |
|
Episode 191 ESMO 2022: PROSPER study of neoadjuvant nivolumab in RCC
|
Sep 10, 2022 |
|
Episode 190: ESMO 2022 Preview
|
Sep 02, 2022 |
|
Episode 189: The Uromigos Paper of the Month - Robotic vs open cystectomy
|
Aug 22, 2022 |
|
Episode 188: The 1st Uromigos Live and Unplugged face-to-face meeting
|
Aug 15, 2022 |
|
Episode 187: Cora Sternberg - The Uromigos Legends Series
|
Aug 15, 2022 |
|
Episode 186: Bernard Escudier - The Uromigos Legends Series
|
Aug 10, 2022 |
|
Episode 185: The Uromigos Paper of the Month - ctDNA in prostate cancer
|
Aug 01, 2022 |
|
Episode 184: Active surveillance in prostate cancer and the seeds of doubt
|
Jul 26, 2022 |
|
Episode 183: Oliver Sartor - The Uromigos Legends Series
|
Jul 18, 2022 |
|
Episode 182: ASCO Kidney Cancer Guidelines
|
Jul 11, 2022 |
|
Episode 181: Relapsed Germ Cell Tumours
|
Jun 27, 2022 |
|
Episode 180: Enzalutamide vs active surveillance in early prostate cancer
|
Jun 20, 2022 |
|
Episode 179: PSMA PET for Lutetium-177 in prostate cancer
|
Jun 20, 2022 |
|
Episode 178: ASCO 2022: Germline variants in men of African descent with prostate cancer
|
Jun 07, 2022 |
|
Episode 177: ASCO 2022: ENZAMET survival update
|
Jun 05, 2022 |
|
Episode 176: ASCO 2022: HER-2 ADCs in Bladder Cancer
|
Jun 05, 2022 |
|
Episode 175: ASCO 2022: Targeting the microbiome in renal cancer
|
Jun 04, 2022 |
|
Episode 174: ASCO 2022: Cell free DNA as a biomarker in bladder cancer
|
Jun 03, 2022 |
|
Episode 173: ASCO 2022: The Atlantis Trial - maintenance cabozantinib in bladder cancer
|
Jun 03, 2022 |
|
Episode 172: ASCO 2022: Adjuvant everolimus in renal cancer
|
Jun 03, 2022 |
|
Episode 171: Antibody drug conjugates in bladder cancer: managing adverse effects
|
May 23, 2022 |
|
Episode 170: APCCC Meeting Summary
|
May 16, 2022 |
|
Episode 169: The Uromigos Paper of the Month - Novel neoadjuvant approaches in UC
|
May 09, 2022 |
|
Episode 168: Mechanisms of response to PD1 therapy in renal cancer
|
May 02, 2022 |
|
Episode 167: Highlights from EIKCS oral session
|
Apr 22, 2022 |
|
Episode 166: Prostate cancer debate: doublet vs triplet first line therapy
|
Apr 18, 2022 |
|
Episode 165: Paper of the Month - ENZAMET quality of life data
|
Apr 06, 2022 |
|
Episode 164: Paper of the Month - what can we learn from R3 ipilimumab/nivolumab in gastric cancer
|
Apr 01, 2022 |
|
Episode 163: The Uromigos Debate - Treatment of favorable risk renal cancer
|
Mar 21, 2022 |
|
Episode 162: Debate - Adjuvant nivolumab for bladder cancer
|
Mar 14, 2022 |
|
Episode 161: Platinum eligibility in urothelial cancer
|
Mar 07, 2022 |
|
Episode 160: APCCC - PMSA PET as a diagnostic
|
Feb 28, 2022 |
|
Episode 159: ASCO GU 2022 Adjuvant and neoadjuvant therapy in renal cancer
|
Feb 19, 2022 |
|
Episode 158: ASCO GU 2022 PROpel Phase III olaparib and abiraterone in renal cancer
|
Feb 19, 2022 |
|
Episode 156: ASCO GU 2022 1st line olaparib and durvalumab in bladder cancer
|
Feb 18, 2022 |
|
Episode 157: ASCO GU 2022 Sasatuzimab and pembrolizumab in bladder cancer
|
Feb 18, 2022 |
|
Episode 154: ASCO GU 2022 MAGNITUDE trial of niraparib and abiraterone in metastatic CRPC
|
Feb 17, 2022 |
|
Episode 155: ASCO GU 2022 ARASENS trial of darolutamide plus chemo vs chemo alone in hormone sensitive advanced prostate cancer
|
Feb 17, 2022 |
|
Episode 153: Overview of PARP inhibition in prostate cancer
|
Feb 10, 2022 |
|
Episode 152: The Uromigos Paper of the Month - Zr-Pembrolizumab PET Imaging
|
Feb 07, 2022 |
|
Episode 151: Bladder Cancer ESMO Guidelines update
|
Jan 31, 2022 |
|
Episode 150: Comparing the quality of life data in renal trials
|
Jan 24, 2022 |
|
Episode 149: Treatment-free survival for ipilimumab and nivolumab
|
Dec 28, 2021 |
|
Episode 148: The Uromigos Paper of the Month - Stereotactic radiotherapy for advanced renal cancer
|
Dec 21, 2021 |
|
Episode 147: Renal Cancer Christmas Special
|
Dec 17, 2021 |
|
Episode 146: Bladder Cancer Christmas Special
|
Dec 13, 2021 |
|
Episode 145: Prostate Cancer Christmas Special
|
Dec 06, 2021 |
|
Episode 144: Pembrolizumab for bladder cancer
|
Dec 02, 2021 |
|
Episode 143: The Uromigos Paper of the Month - Determinants of anti- PD-1 response and resistance in clear cell renal cell carcinoma
|
Nov 17, 2021 |
|
Episode 142: Un resumen de la reciente reunión de Uromigos en Canarias
|
Nov 13, 2021 |
|
Episode 141: Movember - Past, Present and Future
|
Nov 05, 2021 |
|
Episode 140: What is the role of ipilimumab in renal cancer?
|
Oct 29, 2021 |
|
Episode 139: The Uromigos Paper of the Month - Talazoparib in biomarker positive prostate cancer
|
Oct 27, 2021 |
|
Episode 138: Renal Cancer ESMO Guidelines Update
|
Oct 22, 2021 |
|
Episode 137: ESMO 2021: PEACE1 overall survival in prostate cancer
|
Sep 19, 2021 |
|
Episode 136: ESMO 2021: STAMPEDE Abiraterone for high-risk non-metastatic prostate cancer
|
Sep 19, 2021 |
|
Episode 135: ESMO 2021: The STAR Study
|
Sep 19, 2021 |
|
Episode 134: ESMO 2021: The PRISM Study
|
Sep 19, 2021 |
|
Episode 133: ESMO 2021: Cabozantinib and atezolizumab in prostate cancer
|
Sep 18, 2021 |
|
Episode 132: ESMO 2021: Pembro + sEphB4-HAS in bladder cancer
|
Sep 17, 2021 |
|
Episode 131: ESMO 2021: The NORSE Study - Erdafitinib vs Erdafitinib/Cetrelimab
|
Sep 17, 2021 |
|
Episode 130: Larry Einhorn - The Uromigos Legends in GU Cancer series
|
Sep 06, 2021 |
|
Episode 129: Phil Kantoff - The Uromigos Legends in GU Cancer series
|
Sep 02, 2021 |
|
Episode 128: APCCC - PSA relapse post prostatectomy
|
Aug 31, 2021 |
|
Episode 127: APCCC - Adjuvant radiotherapy post prostatectomy
|
Aug 31, 2021 |
|
Episode 126: APCCC - germ line testing and molecular testing in prostate cancer
|
Aug 31, 2021 |
|
Episode 125: The Uromigos Paper of the Month - MRI screening for prostate cancer
|
Aug 27, 2021 |
|
Episode 124: Dean Bajorin - The Uromigos Legends in GU Cancer series
|
Aug 23, 2021 |
|
Episode 123: Maha Hussain - The Uromigos Legends in GU Cancer series
|
Aug 20, 2021 |
|
Episode 122: Nick Vogelzang - The Uromigos Legends in GU Cancer series
|
Aug 16, 2021 |
|
Episode 121: Conflicts of Interest with the podcasts
|
Aug 04, 2021 |
|
Episode 119: EAU - Surgery in urothelial cancer
|
Jul 23, 2021 |
|
Episode 118: Prostate cancer highlights at EAU
|
Jul 20, 2021 |
|
Episode 117: PD1/VEGF adverse event management in renal cancer
|
Jul 20, 2021 |
|
Episode 116: Renal cancer surgery controversies at EAU
|
Jul 14, 2021 |
|
Episode 112: Genomic classifier of high risk African American men with prostate cancer identifying a high-risk population
|
Jul 05, 2021 |
|
Episode 115: Triplet therapy for 1st line metastatic prostate cancer
|
Jul 01, 2021 |
|
Episode 114: Radionucleotides in prostate cancer
|
Jun 18, 2021 |
|
Episode 113: ASCO 2021 Enazlutamide +/- Radium-223
|
Jun 18, 2021 |
|
Episode 111: The randomised phase 3 CANTATA in metastatic renal cancer
|
Jun 08, 2021 |
|
Episode 110: PEACE1 - Triplet therapy in prostate cancer
|
Jun 08, 2021 |
|
Episode 109: Adjuvant pembrolizumab in renal cancer
|
Jun 07, 2021 |
|
Episode 108: Peter O'Donnell gives five year follow-up data on front line pembrolizumab in urothelial cancer
|
Jun 07, 2021 |
|
Episode 107: ASCO 2021: Neoadjuvant chemo/nivolumab as bladder sparing
|
Jun 07, 2021 |
|
Episode 106: Summary of the three bladder sparing neoadjuvant trials at ASCO 2021
|
Jun 07, 2021 |
|
Episode 105: A Phase 2 study of novel immune combinations (ICOS) in bladder cancer
|
Jun 07, 2021 |
|
Episode 104: Plenary Session 177lu-PSMA-617 in Prostate Cancer
|
Jun 06, 2021 |
|
Episode 103: Targeting the microbiome to increase the activity of immune therapy in renal cancer
|
Jun 06, 2021 |
|
Episode 102: Adjuvant therapy in melanoma - how it will help inform the renal community
|
May 28, 2021 |
|
Episode 101: The Uromigos Paper of the Month - Belzutifan in renal cancer
|
May 26, 2021 |
|
Episode 100: The Uromigos 100th Podcast - Looking to the Future
|
May 21, 2021 |
|
Episode 99: Navigating social media from a patients' perspective
|
May 19, 2021 |
|
Episode 98: Bladder cancer from a patient perspective
|
May 19, 2021 |
|
Episode 97: Sacituzumab Govitecan in Bladder Cancer
|
May 04, 2021 |
|
Episode 96: ODAC Bladder Cancer Accelerated Approval Meetings with Andrea Apolo
|
Apr 28, 2021 |
|
Episode 95: ODAC Overview and Bladder Accelerated Approval Meetings with Jorge Garcia
|
Apr 28, 2021 |
|
Episode 94: EIKCS Summary of Day 1
|
Apr 23, 2021 |
|
Episode 93: The Uromigos Paper of the Month - A new risk classification for germ cell cancer
|
Apr 14, 2021 |
|
Episode 92: Second line therapy in advanced RCC
|
Apr 09, 2021 |
|
Episode 91: The Uromigos Paper of the Month - Adjuvant atezolizumab in bladder cancer
|
Mar 26, 2021 |
|
Episode 90: The Uromigos Podcast with QOL Expert David Cella
|
Mar 12, 2021 |
|
Episode 89: The Uromigos Paper of the Month - Pembrolizumab in clear cell and non-clear cell renal cancer
|
Mar 04, 2021 |
|
Episode 88: Career Development in Academic Oncology Part 3 - Walter Stadler
|
Feb 26, 2021 |
|
Episode 87: Career Development in Academic Oncology Part 2 - Monty Pal
|
Feb 26, 2021 |
|
Episode 86: Career Development in Academic Oncology Part 1 - Moshe Ornstein
|
Feb 26, 2021 |
|
Episode 85: The CLEAR Trial
|
Feb 14, 2021 |
|
Episode 84: Prostate cancer highlights from ASCO #GU21 with Chris Sweeney
|
Feb 13, 2021 |
|
Episode 82: Which is the best VEGF/immune combination for first line metastatic renal cancer?
|
Feb 13, 2021 |
|
Episode 83: Is cabozantinib the new standard of care in papillary renal cancer?
|
Feb 13, 2021 |
|
Episode 81: Noah Hahn discusses front line cisplatin-ineligible PD-L1 data from 361 and 130
|
Feb 13, 2021 |
|
Episode 80: Results for Darolutamide in non-metastatic CRPC - the Aramis trial
|
Feb 13, 2021 |
|
Episode 79: Adjuvant nivolumab in operable urothelial cancer
|
Feb 13, 2021 |
|
Episode 78: Enfortumab Vedotin Special: EV301 randomised trial and EV201 in urothelial cancer
|
Feb 12, 2021 |
|
Episode 77: The Uromigos Paper of the Month - Nadofaragene for BCG unresponsive NMIBC
|
Feb 06, 2021 |
|
Episode 76: Tom Hutson discusses lenvatinib and everolimus
|
Jan 22, 2021 |
|
Episode 75: The Uromigos meet APCCC - bone health and bone disease in prostate cancer with Bertrand Tombal
|
Jan 14, 2021 |
|
Episode 74: The Uromigos meet APCCC Round 2: First line treatment - low vs high volume; chemo vs abi/enza
|
Jan 11, 2021 |
|
Episode 73: The Uromigos meet APCCC in a discussion on oligometastatic prostate cancer @APCCC_Lugano
|
Jan 08, 2021 |
|
Episode 72: Uromigos Christmas Special - Renal cancer year in review
|
Dec 21, 2020 |
|
Episode 71: Bladder Cancer Uromigos Christmas Special with Matt Galsky
|
Dec 18, 2020 |
|
Episode 70: The Uromigos Prostate Cancer Christmas Special with Chuck Ryan
|
Dec 11, 2020 |
|
Episode 69: Testis Cancer Christmas Special: 2020 year in review
|
Dec 09, 2020 |
|
Episode 68: Uromigos Paper of the Month - a molecular classification of renal cancer in Cancer Cell
|
Dec 08, 2020 |
|
Episode 67: The Third Uromigos Debate - PD1/VEGF vs PD1/CTLA4 for front line renal cancer
|
Nov 17, 2020 |
|
Episode 66: Uromigos Paper of the Month - Two papers in Nature Medicine on neoadjuvant immune combinations in bladder cancer
|
Nov 09, 2020 |
|
Episode 65: Review of the International Kidney Cancer Symposium
|
Nov 02, 2020 |
|
Episode 64: The Second Uromigos debate with Nobel Laureate Bill Kaelin on new biomarker vs new drugs in RCC
|
Oct 28, 2020 |
|
Episode 63: The First Uromigos Debate: front line immune therapy vs maintenance avelumab in bladder cancer
|
Oct 09, 2020 |
|
Episode 62: James Eastham's Uromigos Paper of the Month - Prostatectomy +/- Neoadjuvant Chemo
|
Oct 06, 2020 |
|
Episode 61: Nick James discusses the latest update of the STAMPEDE study
|
Sep 21, 2020 |
|
Episode 60: Cora Sternberg discusses AMG 160 - a bispecific antibody in prostate cancer
|
Sep 21, 2020 |
|
Episode 59: Ipatercertib in biomarker positive castrate resistant prostate cancer
|
Sep 20, 2020 |
|
Episode 58: Brilliant ESMO discussant Richard Cathomas talks to Brian and Tom about the meaning of DANUBE and KN362
|
Sep 19, 2020 |
|
Episode 57: Toni Choueiri - cabo & nivo vs sunitinib in metastatic clear cell renal cancer
|
Sep 19, 2020 |
|
Episode 56: Matt Galsky and Tom Powles discuss ESMO 2020 immune therapy data in bladder cancer
|
Sep 19, 2020 |
|
Episode 55: The Uromigos Paper of the Month - Cabozantinib in Bladder Cancer by Dr. Andrea Apolo
|
Aug 31, 2020 |
|
Episode 54: Biomarkers in prostate cancer with Chris Sweeney
|
Jul 24, 2020 |
|
Episode 53: Still in Boston - biomarkers in bladder cancer
|
Jul 24, 2020 |
|
Episode 52: The Final Stop - Boston: David McDermott discusses biomarkers in renal cancer in the era of immune therapy
|
Jul 24, 2020 |
|
Episode 51: The Uromigos World Tour is in Norway with Jan Oldenburg - discussing key topics in testis cancer
|
Jul 18, 2020 |
|
Episode 50: The Uromigos World Tour in London with renal cancer surgery
|
Jul 15, 2020 |
|
Episode 49: The Tour remains in Germany with Oliver Grimm and renal cancer
|
Jul 14, 2020 |
|
Episode 48: ...and then Germany - Jürgen Gschwend discusses cystectomy for urothelial cancer
|
Jul 10, 2020 |
|
Episode 46: The Uromigos World Tour in Spain discussing SOGUG and Renal Cancer with Cristina Suarez
|
Jul 09, 2020 |
|
Episode 45: The Uromigos World Tour arrives in Japan
|
Jul 03, 2020 |
|
Episode 44: The Uromigos World Tour in Australia - Talking with Ian Davis about prostate cancer and ANZUP
|
Jul 03, 2020 |
|
Episode 43: The Uromigos World Tour in Singapore with Ravi Kanesvaran
|
Jun 29, 2020 |
|
Episode 42: The Uromigos in Argentina
|
Jun 28, 2020 |
|
Episode 41: The Uromigos World Tour lands in Brazil - Fernando Maluf talks about prostate cancer and recent research in Brazil
|
Jun 25, 2020 |
|
Episode 40: The Uromigos World Tour moves to France - Bernard Escudier discusses 2nd line therapy in renal cancer and Tivozanib
|
Jun 22, 2020 |
|
Episode 39: The Uromigos World Tour - Renal Cancer and IMDC Risk with Danny Heng in Calgary
|
Jun 18, 2020 |
|
Episode 38: The Uromigos Virtual World Tour - starting in Vancouver with Atezolizumab in NMIBC
|
Jun 16, 2020 |
|
Episode 37: Regoratinib (FGFR inhibitor) and Atezolizumab in UC with Jonathan Rosenberg
|
Jun 01, 2020 |
|
Episode 36: Dr. Tian Zhang discusses three ASCO bladder cancer abstracts with immune therapy/targeted therapy combinations
|
Jun 01, 2020 |
|
Episode 35: Maintenance Avelumab in Bladder Cancer (LBA1)
|
May 31, 2020 |
|
Episode 34: Savolitinib in Renal Papillary Cancer - A Major Breakthrough?
|
May 30, 2020 |
|
Episode 33: Adjuvant Atezolizumab in Urothelial Cancer
|
May 29, 2020 |
|
Episode 32: A Phase 2 Study of PSMA PET in Prostate Cancer with Thomas Hope from ASCO 2020
|
May 29, 2020 |
|
Episode 31: A Phase 2 Study of Nivolumab with the Addition of Ipilimumab Upon Progression in Renal Cancer
|
May 29, 2020 |
|
Episode 30: Update on Axitinib plus Pembrolizumab in Renal Cancer (KEYNOTE 426)
|
May 29, 2020 |
|
Episode 29: PSMA PET at ASCO 2020 with Mike Morris
|
May 29, 2020 |
|
Episode 28: Targeting VHL Syndrome Renal Cancer with a HIF Inhibitor - A Game Changer
|
May 29, 2020 |
|
Episode 27: COVID-19 in > 1000 Cancer Patients with Jeremy Warner (CCC-19)
|
May 29, 2020 |
|
Episode 26: Joaquim Bellmunt and Muscle Invasive Bladder Cancer prior to ASCO 2020
|
May 19, 2020 |
|
Episode 25: Dr. Tian Zhang discusses first line treatment for renal cancer and the PDIGREE Trial
|
May 19, 2020 |
|
Episode 24: A Study of COVID-19 in Lung Cancer Shows High Mortality
|
Apr 28, 2020 |
|
Episode 23: Atezolizumab and Enzalutamide versus Enzalutamide Prostate Cancer
|
Apr 28, 2020 |
|
Episode 22: COVID-19 and Cardiovascular Disease
|
Apr 22, 2020 |
|
Episode 21: Treating cancer patients over the next year in the era of COVID-19
|
Apr 15, 2020 |
|
Episode 20: Treating GU Cancer Patients with acute COVID-19 Infection
|
Apr 15, 2020 |
|
Episode 19: Professor Monty Pal discusses the treatment of non-clear cell renal cancer
|
Apr 15, 2020 |
|
Episode 18: COVID-19: Addressing Renal Cancer Patients’ Concerns
|
Apr 06, 2020 |
|
Episode 17: Dr. Toni Choueiri discusses cancer trials and meetings during COVID-19
|
Apr 02, 2020 |
|
Episode 16: Treatments and Trials for COVID-19
|
Mar 31, 2020 |
|
Episode 15: COVID-19 and Bladder Cancer Surgery
|
Mar 28, 2020 |
|
Episode 14: A Discussion about Tocilizumab and COVID-19 with Dr. Nick Mark from Seattle
|
Mar 24, 2020 |
|
Episode 13: COVID-19 and Hydroxychloroquinine Existing Data and Ongoing Trials
|
Mar 23, 2020 |
|
Episode 12: COVID-19 in Cancer Patients - The Seattle Experience
|
Mar 20, 2020 |
|
Episode 11: COVID-19 and Immune Checkpoint Inhibitors for the Treatment of Cancer
|
Mar 16, 2020 |
|
Episode 10: COVID-19 and Renal Cancer: A Patient's Perspective
|
Mar 16, 2020 |
|
Episode 9: COVID-19 and Cancer: An International Perspective
|
Mar 16, 2020 |
|
Episode 8: COVID-19 and Cancer Patients
|
Mar 13, 2020 |
|
Episode 7: The First Uromigos Prostate Cancer Podcast
|
Feb 27, 2020 |
|
Episode 6: Urothelial Cancer Highlights from ASCO GU 2020
|
Feb 26, 2020 |
|
Episode 5: Renal Highlights from ASCO GU 2020
|
Feb 24, 2020 |
|
Episode 4: Treatment Choices in Front Line Advanced Renal Cancer
|
Feb 11, 2020 |
|
Episode 1: Introduction to Uromigos Podcasts
|
Feb 11, 2020 |
|
Episode 2: The Current role of IO in Front-line Advanced Urothelial Cancer
|
Feb 11, 2020 |
|
Episode 3: Pembrolizumab in Non-Muscle Invasive Bladder Cancer
|
Feb 11, 2020 |